
Opinion|Videos|July 29, 2024
Out of Pocket Costs Associated with Biosimilar Use
The panel discusses out of pocket costs and the impact of the 340b program for various patient types.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Inside the VA’s Hub-and-Spoke Model for Multiple Sclerosis Care: Rebecca Spain, MD
2
Newly Identified RTEL1 Variant Could Broaden Genetic Landscape of Familial PF
3
Flow Cytometry Tracks CAR T-Cell Therapy Persistence in Aggressive LBCL
4
2025 Hypertension Guideline Updates Presented at AHA Scientific Sessions
5













































